Chemours CEO buys 3,378 company shares
Chemours Co Chief Executive Officer and director Denise Dignam purchased 3,378 shares of Chemours common stock on 2026-08-11 at $14.95 per share in an open-market transaction.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Chemours Co Chief Executive Officer and director Denise Dignam purchased 3,378 shares of Chemours common stock on 2026-08-11 at $14.95 per share in an open-market transaction. Following this trade, she directly owns a total of 339,916.3423 shares, which includes directly owned shares, restricted stock units and dividend equivalent units, with the total adjusted to correct an administrative error in prior reports.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock F1, F2 | 3,378 | $14.95 | $51K |
Footnotes (2)
- F1. Includes directly owned shares, restricted stock units and dividend equivalent units.
- F2. The total holdings have been adjusted to correct an administrative error in prior Form 4s.
Key Figures
Key Terms
restricted stock units financial
dividend equivalent units financial
administrative error regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Chemours (CC) CEO Denise Dignam report?
Did the Chemours (CC) Form 4 mention any correction to prior reported holdings?
AI-generated analysis. How Rhea-AI works. Not financial advice.